Novel blood test detects lung cancer traces long before scans

by Elsevier

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

Despite advances in early-stage lung cancer treatment, a significant number of patients experience disease recurrence after surgery or initial therapy. A study has now demonstrated that a blood test (liquid biopsy) can reliably detect lingering lung cancer traces even in the earliest clinical stages, long before a tumor is large enough to show up on a scan. This real-time genetic monitoring detailed in an article appearing in The Journal of Molecular Diagnostics, accurately predicts relapse risk, opening a window for timely, personalized therapeutic interventions.

Non–small-cell lung cancer (NSCLC) is the most common type of lung cancer and remains the major cause of cancer-related death. Small tumors in patients with early-stage NSCLC (I to II) are usually surgically removed, and survival rates are reasonably high. However, even in stage I, disease recurrence rates range between 5% and 19%, and imaging follow-up remains standard of care.

"As oncology shifts toward personalized risk-adapted care, liquid biopsies are emerging as a critical tool to bridge the gap between treatment completion and clinical recurrence," explains lead investigator Matija Snuderl, M.D., Department of Pathology, NYU Langone Health and Grossman School of Medicine, and Laura and Isaac Perlmutter Cancer Center, New York, New York.

"In our study, we monitored patients with lung cancer across treatment stages using serial blood draws to track circulating tumor DNA (ctDNA) levels. By analyzing tumor-specific signatures of ctDNA shed by tumor cells into the bloodstream, we evaluated how effectively liquid biopsy predicts relapse compared to standard imaging."

The most significant finding was that a positive test result for tumor DNA served as a highly sensitive biomarker for minimal residual disease, detecting microscopic recurrence months before scans showed physical tumors, while a clear (negative) test strongly correlated with sustained remission.

"As a surgeon, I follow my patients very closely, and I want to know as soon as possible if the cancer has come back. Unfortunately, even the earliest-stage patients risk recurrence," notes co-lead investigator Harvey I. Pass, M.D., Department of Cardiothoracic Surgery, NYU Langone Health, New York, New York. "Our study's findings highlight just how sensitive and specific liquid biopsy can be when integrated into routine post-treatment monitoring, even in the earliest stages of lung cancer. This is of critical importance for deciding on postoperative treatments."

Snuderl adds, "Minimal residual disease testing via liquid biopsy represents a fundamental shift in postoperative care. It gives pathologists a powerful tool to diagnose disease before it appears on imaging and equips clinicians with actionable insights to personalize surveillance and intervention strategies for every individual patient."

The study highlights the implications of these blood tests for every stage of the patient journey:

• Clinicians can identify high- or low-risk patients far earlier.
• Test results help guide targeted treatment for patients with detectable residual disease, while potentially sparing those with clear test results from the burden of unnecessary overtreatment and toxicity.
• These liquid biopsies offer actionable clarity, reducing the anxiety of waiting between periodic imaging scans by replacing uncertainty with clear biological data.
• Early detection of relapse allows treatment to restart when the disease burden is extremely low, substantially improving long-term outcomes and survival prognosis.

The WGS liquid biopsy technology used in this study was developed by co-investigator Asaf Zviran, Ph.D., C2i Genomics Inc., New York, New York, who concludes, "The true promise of residual disease monitoring has always been to identify patients at high risk of recurrence early enough to enable curative intervention—before the cancer has an opportunity to spread, evolve and diversify."

Publication details

Matija Snuderl et al., Predicting Recurrence of Stage IA Lung Adenocarcinoma Using Circulating Tumor Cell–Free DNA Whole-Genome Mutational Signatures, The Journal of Molecular Diagnostics (2026). DOI: 10.1016/j.jmoldx.2026.07.003

Journal information: Journal of Molecular Diagnostics

Key medical concepts

Neoplasm, ResidualLiquid BiopsyCirculating Tumor DNACarcinoma, Non-Small-Cell Lungdisease recurrence

Clinical categories

OncologyLaboratory medicine Provided by Elsevier Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Novel blood test detects lung cancer traces long before scans (2026, October 20) retrieved 20 October 2026 from https://medicalxpress.com/news/2026-10-blood-lung-cancer-scans.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.